Amy Rosenberg

Company: Epivax

Job title: Senior Director Immunology

Seminars:

Clinical Risk Assessments Considerations for Immunogenicity & Tolerogenicity for LNP Vectored Therapeutics Vaccine 9:00 am

Evaluating the potential for the LNP vector to induce antigen-presenting cells that may trigger unwanted immune responses Analyzing the likelihood of the vaccine inducing the production of antibodies against the therapeutic antigen Understanding the persistence of the tolerogenic response induced by the LNP-based vaccine over timeRead more

day: Day One